Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
COVID-19 and the Liver, “it's complicated - Ep 29
Matt Kelly, Chief Innovation Officer at Perspectum, Ltd., joins the Surfers to discuss early findings from the COVERSCAN study which looks at the relationship between COVID-19 infection…
Wild Times in NASH-Ville Part 3: Better Days ARE Ahead! Ep 28
Stephen Harrison leads the Surfers through a review of FGF-21s and other exciting drug development news.
Stephen Harrison starts this week's discussion reviewing the recent announcement …
Crystal Ball Tells Us The Most Important Stories Of Autumn - Ep 27
The Surfers discuss four issues that are likely to affect how our thinking about NASH diagnosis, education, and treatment might evolve over the next three months.
Naim Alkhouri joins the…
"Beond the Biopsy" How NASH Therapy Will Improve When Non-Invasive Tests Become The Standard - Ep 26
The Surfers discuss the Global Liver Institute's campaign to educate and motivate key stakeholder groups on the value of non-invasive liver testing.
Donna Cryer, President and CEO of th…
What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25
The Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular disease, is the leading cause of death for NA…
EASL Digital ILC 2020 Wrap-Up: A Complicated Picture Emerges - Ep 24
Professors Joern Shcattenberg and Vlad Ratziu join the Surfers to discuss the lessons and findings we can take away from Digital ILC 2020.
What happens when seven people with diverse and…
Digital ILC Day Three Highlights: Late breakers, COVID and more - Ep 23
SurfingNASH's Digital ILC coverage ends with three late-breaking drug presentations, a discussion of EASL's COVID efforts, and insights on patient management.
Professor Joern Schattenber…
Digital ILC Day Two Highlights: A Fork in the Road - Ep 22
Drugs in development and diagnostics show promise but healthcare has far to go in identifying and treating patients in need.
Professor Vlad Ratziu joins the Surfers to discuss Day Two's …
Digital ILC Day One Highlights: Much to Think About - Ep 21
One day into the first-ever digital major conference, the Surfers review six presentations and one interactive session. A lot was learned, much of which did not fit into neat categories…
How will Digital ILC be different from past conferences? - Ep 20
The group discusses the plusses and minuses of digital conferences compared to traditional in-person events.
Digital ILC starts Thursday, August 27. Donna Cryer, who oversaw the first Di…
What NASH patients want from outside the healthcare system - Ep 19
The second part of the "What NASH patients want" series focuses on the future of healthcare apps and the role government agencies such as FDA, NIH, CMS, and EMEA can play in providing h…
What NASH Patients Want From the Healthcare System - Ep 18
Patient advocates discuss how doctors and other providers can serve patient needs better
Guest surfer Anthony Villiotti, President of NASH kNOWledge, Inc. joins the Surfers. Tony and Sur…
Previewing EASL: Part 2 - Ep 17
Donna Cryer, President & CEO of the Global Liver Institute, and Louise Campbell, Founder of Tawazun Health, become Surfing regulars in an episode focused on the pivotal papers at EASL's…
Nurses Helping NASH Patients - Ep 16
The Surfers focus on steps Allied Health Professions and passionate physicians can take to improve lifestyle compliance with #NASH and #NAFLD therapies. The group explores whether the h…
Previewing EASL: Part 1 - Ep 15
FOCUS: Some of the presentations that will make NASH/NAFLD news next month
Transplant hepatologist Naim Alkhouri joins the Surfers in discussing a dozen intriguing paper or session title…
Respect For The Liver - Ep 14
NASH is not merely a byproduct of obesity.
The role the liver plays in non-liver comorbidities is complex and important. Join the Surfers as they give the liver the respect it’s due. “T…
Diagnosing Diagnostics III: Better Tools on the Way - Ep 13
FOCUS: Three sets of tools that will improve NASH disease understanding.
The Surfers return to diagnostics once more. This time, they explore the utility of novel blood and serum tests,…
What Does “No” Mean to FDA? - Ep 12
Decoding the message of Intercept’s Complete Response Letter
Former FDA Director Brian Harvey joins the Surfers to discuss what obeticholic acid’s rejection might mean for other NASH med…
Crystal Ball Tells Us the Most Important Story of the Summer - Ep 11
CONSENSUS: the big story will be the regrowth of COVID-19 in the US and its implications.
The Surfers discuss different elements of the evolving COVID-19 story — what it feels like to li…
Diagnosing Diagnostics II: Tools vs. Teaching - Ep 10
What would create greater value for patients and providers?
Professor Mary Rinella of Northwestern University and Suneil Hosmane of GenFit join Stephen, Louise, and Roger to explore whic…